Full-Time

Investor Relations Analyst

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

No salary listed

Research Triangle Park, Durham, NC, USA

Hybrid

At least three days per week in the office are required; in-office requirements may increase based on business needs.

Bachelor's, Master's

Category
Business & Strategy (2)
,
Required Skills
Bloomberg
Microsoft Office
CRM
Social Media
Financial analysis
Word/Pages/Docs
Workiva
Excel/Numbers/Sheets
Financial Modeling
PowerPoint/Keynote/Slides

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Requirements
  • A Bachelor's Degree in business, communications, or sciences.
  • At least 2 years of relevant experience in biotech, capital markets, investor relations, financial planning and analysis, communications, or securities analysis with a Bachelor's Degree, or at least 0 years of relevant experience in those fields with a Master's Degree.
  • Strong interpersonal skills, intellectual curiosity, and effective verbal and written communication abilities, with the ability to build positive working relationships and convey information clearly to team members and stakeholders.
  • The ability to receive, incorporate, and grow from real-time feedback and constructive criticism, demonstrating a commitment to continuous learning and professional development.
  • The ability to work as an energetic, efficient, and resourceful team player and individual contributor with a strong desire to learn, develop new skills, and expand knowledge within the field.
  • Strong attention to detail with the ability to manage multiple assignments and meet deadlines while effectively navigating incomplete, evolving, or ambiguous information with appropriate guidance when needed.
  • Solid working knowledge of financial modeling and valuation techniques used by securities analysts to assess a company's operating and financial performance and support investment-related analysis.
Responsibilities
  • Support the preparation and enhancement of communications materials, including quarterly earnings collateral, press releases, corporate presentations, frequently asked questions documents, and product and pipeline fact sheets.
  • Contribute to maintaining, updating, and improving the investor relations website and pipeline website.
  • Support the development of social media content that supports investor relations activities.
  • Collaborate with the investor relations team to prepare and develop new investor communications materials.
  • Participate in interactions with new and existing sell-side analysts covering United Therapeutics and other biotech companies.
  • Contribute to collecting and maintaining sell-side analyst models used to provide consensus financial data to management and external stakeholders.
  • Monitor company-specific and industry-wide sell-side research, including scientific content, and track and provide updates on changes in peer performance.
  • Help develop and support an active investor relations calendar, including the planning, logistics, and execution of investor conferences, investor events, non-deal roadshows, and other communication events.
  • Assist with scheduling investor calls and meetings and provide support for and participate in meetings with institutional investors.
  • Work with external vendors and the investor relations team to support efforts to target new institutional investors.
  • Collaborate with the investor relations team to implement a sell-side and institutional investor outreach program and benchmark the program against peer activities.
  • Support the preparation of background information for key internal spokespeople in advance of meetings with investors and other external stakeholders.
  • Monitor industry and competitor newsflow and provide relevant updates to the investor relations team.
  • Collaborate with key subject matter experts within the company to understand activities that may be relevant for communication to external stakeholders.
  • Maintain and update the Investor Relations Quarterly Report distributed to senior executives and the board of directors.
  • Track company stock performance and valuation relative to peer companies.
  • Help prepare the investor relations team for investor, analyst, and internal meetings.
  • Maintain the investor relations customer relationship management tool.
  • Contribute to the development and implementation of external corporate communication strategies that support current business goals and objectives in collaboration with company stakeholders.
  • Evaluate current processes within the Investor Relations department and make recommendations for improvements, benchmarking investor relations activities against those of current and aspirational peers.
  • Perform all other duties as assigned.
Desired Qualifications
  • A Master's Degree in business, communications, or sciences.
  • At least 1 year of prior public company investor relations experience, sell-side experience, or operational experience within another biotech company.
  • Proficiency in Microsoft Office Suite, including Excel, PowerPoint, and Word, and familiarity with investor relations and financial intelligence platforms such as Bloomberg, FactSet, S&P Global/Ipreo, and Workiva.
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved LungFX on June 29, 2026, with services targeted for 2027.
  • Second-quarter 2026 net income rose to $333 million despite softer revenue.
  • United Therapeutics bought Thymmune for $140 million, expanding transplant-tolerance programs.

What critics are saying

  • Tyvaso net sales fell in Q2 2026 as Yutrepia launches intensified.
  • Liquidia and Boehringer lawsuits threaten Treprostinil revenues and sales execution through 2027.
  • Tyvaso concentration makes a bad PAH cycle or trial failure existential.

What makes United Therapeutics Corporation unique

  • LungFX approval makes United Therapeutics first in centralized EVLP.
  • Thymmune acquisition deepens its organ-tolerance and regenerative-medicine moat.
  • Cash-rich rare-disease franchise funds organ manufacturing and xenotransplantation bets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Investor's Business Daily
Aug 12th, 2026
Liquidia drops 4% despite $170M Yutrepia sales beat, misses earnings by 2 cents

Liquidia shares fell more than 4% on Wednesday despite the company's lung disease drug Yutrepia beating second-quarter sales expectations. The treatment generated $170.4 million in sales, growing 31% and surpassing forecasts of $166.4 million. However, the company posted earnings of 74 cents per share, slightly missing expectations of 76 cents. Yutrepia, which launched in June 2025, competes with United Therapeutics' Tyvaso in treating high blood pressure in the lungs. Since launch, Liquidia has received approximately 5,900 new patient prescriptions, with more than 5,000 patients starting treatment. Over 1,100 physicians now prescribe the drug. Liquidia stock has gained 155% year-to-date and ranks second on the IBD 50 list of elite growth stocks.

Yahoo Finance
Aug 7th, 2026
United Therapeutics reports $333M net income and $7.27 EPS as ralinepag files for FDA approval

United Therapeutics reported second-quarter 2026 results showing sales of $783.3 million, a slight year-on-year decline, whilst net income rose to $333 million and diluted earnings per share increased to $7.27. The company continued share repurchases under its $1.50 billion buyback programme, retiring 5.84% of shares. The biotech firm also published positive phase 3 ADVANCE OUTCOMES data for investigational pulmonary arterial hypertension therapy ralinepag and filed with the FDA. The stronger earnings per share partly reflects the shrinking share count from buybacks. Analysts remain divided on the company's future, with some projecting only 1.2% annual revenue growth and $1.4 billion earnings by 2029, citing concerns about its concentrated portfolio of pulmonary drugs and regulatory uncertainties.

Yahoo Finance
Jul 23rd, 2026
United Therapeutics appoints ex-National Academy of Medicine president Victor Dzau to board

United Therapeutics Corporation has appointed Victor Dzau to its board of directors, effective 22 July 2026. Dr Dzau recently completed a 12-year term as president of the National Academy of Medicine and previously served as chancellor for health affairs at Duke University and president of the Duke University Health System. Dr Dzau is recognised globally as a physician-scientist whose research laid the foundation for ACE inhibitors. He pioneered gene therapy for vascular disease and currently studies cardiac regeneration. Martine Rothblatt, chairperson and chief executive officer of United Therapeutics, said Dr Dzau is uniquely capable of guiding the company in its mission of developing transplantable organs and organ alternatives for patients with end-stage organ failure.

Yahoo Finance
Jul 11th, 2026
United Therapeutics wins FDA approval for LungFX device amid questions over valuation

United Therapeutics is under scrutiny after the US FDA approved its LungFX device for centralised ex vivo lung perfusion. The stock has shown strong momentum, with a year-to-date return of 10.13% and a one-year total shareholder return of 85.12%, though short-term prices have eased slightly. The company closed at $547.06, against a narrative fair value of $665.23, suggesting an 18% undervaluation. The valuation gap depends on whether LungFX, Tyvaso, and the broader pulmonary and organ platforms can drive future earnings. United Therapeutics' pipeline includes studies in progressive fibrosis, next-generation delivery platforms, and organ manufacturing technologies. However, the company faces risks from potential trial setbacks and drug pricing reforms that could impact profitability and cash flows.

Yahoo Finance
Jul 8th, 2026
United Therapeutics acquires Thymmune for $140M to advance organ transplant innovation

United Therapeutics Corporation acquired Thymmune Therapeutics for $140 million in cash, with potential additional earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031. Thymmune develops regenerative thymic cell therapies using human-induced pluripotent stem cells. The acquisition expands United Therapeutics' organ transplantation capabilities. The company focuses on treating life-threatening diseases, including pulmonary arterial hypertension, whilst addressing the global organ shortage through xenotransplantation, 3D bioprinting, and ex vivo lung perfusion technologies. Separately, the FDA granted premarket approval for LungFX, which Leerink Partners described as a regulatory advancement supporting the company's long-term organ manufacturing strategy. Leerink maintains an Outperform rating on United Therapeutics shares.